Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Author:
Funder
Irish Cancer Society
Health Research Board
North East Cancer Research and Education Trust
Science Foundation Ireland
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference38 articles.
1. Studies of the HER-2 / neu Proto-Oncogene in Human Breast and Ovarian Cancer;DJ Slamon;Science,1989
2. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer;N Elster;Breast Cancer Research and Treatment,2015
3. Adjuvant trastuzumab in HER2-positive breast cancer;D Slamon;N Engl J Med,2011
4. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial;M Piccart-Gebhart;J Clin Oncol,2016
5. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;EA Perez;J Clin Oncol,2014
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+ Breast Cancer;Mini-Reviews in Medicinal Chemistry;2023-06
2. Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics;Cell Death Discovery;2023-02-09
3. HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment;Cancers;2023-01-26
4. Chemotolerance of Breast Cancer and Its Management by Personalized Medicine;Breast Cancer: From Bench to Personalized Medicine;2022
5. Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer;Current Cancer Drug Targets;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3